Akèy › Metiyè › Molecular and Cellular Biologists › Pleasanton, CA
Molecular and Cellular Biologists nan Pleasanton, CA: Salè H-1B
48 aplikasyon kondisyon travay pou okipasyon sa a ak yon sit travay nan Pleasanton, CA. Salè baz medyàn ofri $112,404; mwatye mitan $86,193–$140,250.
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $85,197 |
| Nivo II (kalifye) | $112,258 |
| Nivo III (eksperyans) | $140,500 |
| Nivo IV (plen kompetans) | $170,000 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| 10x Genomics, Inc. | 13 | $140,000 |
| Thermo Fisher Scientific Inc. | 7 | $85,350 |
| Roche Molecular Systems, Inc. | 6 | $85,197 |
| LifeFoundry, Inc. | 5 | $117,210 |
| Roche Sequencing Solutions, Inc. | 4 | $119,704 |
| Bio-Rad Laboratories, Inc. | 4 | $112,549 |
| CooperVision, Inc. | 2 | $133,020 |
| Place Genomics Corporation | 2 | $170,000 |
| Amador Bioscience, Inc. | 1 | $65,125 |
| DiaCarta, Inc. | 1 | $101,816 |
| Acrobiosystems Inc. | 1 | $107,600 |
| OPM Biosciences Inc. | 1 | $95,000 |
| Promptbio, Inc. | 1 | $150,000 |
Tit travay
- Scientist5
- Scientist II, Molecular Biology3
- Research Associate 22
- Senior Scientist2
- Biosystem Scientist2
- Staff Computational Biologist2
- Scientist III, Molecular Biology2
- Senior Staff Scientist2
- Biosystem Research Scientist2
- Biospecimen Senior Specialist2
- Principal Scientist I2
- Statistical Programmer1
- Principal Scientist1
- Computational Biologist 21
- Bioinformatics Scientist II1
Pwonse H-1B nan Pleasanton, CA →
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).